 CRANFORD, N.J., June 7, 2021 PRNewswire -- Citius Pharmaceuticals, Inc. Citius or the Company Nasdaq: CTXR, a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it is set to be added to the Russell 2000 Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021. 